stockrowRegeneron Pharmaceuticals, Inc. (REGN) vs Royalty Pharma PLC (RPRX)
- Regeneron Pharmaceuticals, Inc. REGN 907.36 +0.49%
- Royalty Pharma PLC RPRX 67.70 +0.19%
Regeneron Pharmaceuticals, Inc. and Royalty Pharma PLC are both Biotechnology companies. Regeneron Pharmaceuticals, Inc. is the larger, with a market value of $93.4B against $39.0B — 2.4× the size. Regeneron Pharmaceuticals, Inc. trades at the lower P/E: 19.2× against 44.8×. Regeneron Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 18.6% against 11.4%. Regeneron Pharmaceuticals, Inc. has the higher net margin (28.5% vs 0.00%) and the higher return on invested capital (11.6% vs 5.24%). Both pay a dividend; Royalty Pharma PLC yields more (1.37% vs 0.41%). Across the 23 metrics below, Regeneron Pharmaceuticals, Inc. leads on 17 and Royalty Pharma PLC on 6.
Valuation
Profitability
| Metric | REGN | RPRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 85.77% | 100.00% | 65.16% |
| Operating margin | 28.79% | 57.14% | 0.00% |
| Net margin | 28.51% | 0.00% | 0.00% |
| Free cash flow margin | 21.47% | 113.11% | 0.00% |
| Return on equity | 14.95% | 0.00% | (50.12%) |
| Return on assets | 11.39% | 0.00% | (45.60%) |
| Return on invested capital | 11.61% | 5.24% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack